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Choroidal Melanoma: Screening for metastasis and frequency of incidental
second primary cancer diagnosis.
Abstract
Background: Choroidal melanoma is the most common primary intraocular malignancy in adults. This
case report reviews clinical diagnostic features, imaging techniques, treatment, prognosis, and systemic
work-up of choroidal melanomas. It also addresses choroidal melanoma metastasis and the incidental
finding of second primary cancers through whole-body screening.
Case Report: A 71-year-old white male reported to the Cleveland VA Medical Center optometry retina
clinic for a second opinion exam of an asymptomatic choroidal lesion in the right eye. The lesion was a 6
mm gray choroidal mass in the inferior peripheral fundus, with orange pigmentation, retinal pigmented
epithelial hypertrophy along the superior border, and drusen. B-scan ultrasound showed a mass that was
elevated by 2.5 mm with moderate reflectivity, suggestive of choroidal melanoma.
Conclusion: Early diagnosis of choroidal melanoma is important due to improved survival rates in those
diagnosed when the choroidal melanoma is small. In addition to the clinical assessment, diagnosis may
be aided by ancillary imaging such as OCT. Prognosis generally is poor due to late diagnosis and is
dependent on choroidal melanoma size, genetic profile, and presence of metastasis. Whole-body
screening for metastasis leads to the discovery of additional primary tumors at a rate nearly equal to that
of metastasis.
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INTRODUCTION
Choroidal melanoma is the most common primary intraocular malignancy in
adults. Diagnosis of a choroidal melanoma is primarily made from observation of
classic clinical features, including a pigmented dome-shaped tumor with subretinal
fluid, orange pigment, and thickness greater than 2 mm. Larger choroidal
melanoma size is related to a lower survival rate. Conversely, early diagnosis leads
to early treatment and greater chance of patient survival. Incidence of metastasis is
25% and 34% at five and ten years respectively, while an additional primary cancer
is discovered in about 10% of patients.1 This case report reviews clinical diagnostic
features, imaging techniques, treatment, prognosis, and systemic work-up of
choroidal melanomas.
CASE REPORT
A 71-year-old white male reported to the Cleveland VA Medical Center optometry
retina clinic for a second opinion of an asymptomatic choroidal lesion in the right
eye. The patient’s ocular history was significant for phototoxic maculopathy in the
right eye secondary to welding, a low-risk glaucoma suspect, and allergic
conjunctivitis. Best-corrected visual acuities were stable from baseline at 20/40 in
the right eye and 20/20 in the left eye. The anterior segment evaluation was
remarkable for trace papillae of the inferior palpebral conjunctiva. Dilated fundus
examination revealed unremarkable findings for all structures in the left eye. The
right eye revealed a stable macular scar and a 6 mm gray choroidal mass of the
peripheral fundus inferiorly with orange pigmentation, retinal pigmented epithelial
hypertrophy along the superior border, and drusen. B-scan ultrasound (Figure 1)
was performed and showed a mass that was elevated by 2.5 mm with moderate
reflectivity.
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Figure 1: B-scan ultrasound of the patient’s choroidal melanoma showing the elevated choroidal
mass with medium reflectivity.

Ocular coherence tomography (OCT) revealed a peripheral elevated choroidal
lesion via line scan. Because the mass was in the peripheral fundus, OCT with raster
scanning and enhanced depth imaging, as well as autofluorescence, were difficult
to obtain (Figure 2).

Figure 2: Spectralis OCT line scan showing the peripheral elevated choroidal melanoma.

The diagnosis of choroidal melanoma was made, and the patient was referred to
an ocular oncologist at the Cleveland Clinic Foundation Cole Eye Institute. The
ocular oncologist confirmed the diagnosis of choroidal melanoma, which was 7.5
x 6.5 x 2.5 mm in size with mild vascularity and medium internal reflectivity.
Biopsy of the lesion confirmed a choroidal melanoma. Treatment was initiated with
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a radioactive plaque that was sutured into place and delivered radiation for over
seventy hours before removal.
Same-day CT scan of the chest/abdomen/pelvis was performed at the Cole Eye
Institute. The report from urology stated, “suspicion of metastatic disease through
the presence of a heterogeneously enhancing prostate with possible extracapsular
extension, two adrenal nodules, and retro-peritoneal, retro-aortic, and pelvic
lymphadenopathy.” Care was then coordinated with the Cleveland VA urology
service. Biopsy of the prostate revealed stage 3 adenocarcinoma of the prostate with
perineural invasion. The patient was then initiated on hormone therapy. Treatment
options were discussed with the patient, including resection and radiation.
The patient was seen four months after the initial diagnosis at the Cleveland
VAMC optometry retina clinic. A large area of scarring and chorioretinal atrophy
with retinal hemorrhages was seen in the area of the treated melanoma and an
overall improvement in the lesion from the initial encounter was observed. The
patient was scheduled to follow up again in 3 months.
DISCUSSION
Choroidal melanomas are uncommon, with an incidence of about 6 in 1 million in
the United States, with 98% of those cases occurring in Caucasians. The median
age of diagnosis is about 55 years and there is a slight predilection for men in almost
all age groups.1
The diagnosis of choroidal melanoma is primarily based on ophthalmoscopic
findings. Differential diagnoses must include choroidal nevus, congenital
hypertrophy of the retinal pigment epithelium (CHRPE), subretinal blood,
choroidal detachment, hemangiomas, metastatic carcinoma, and lymphoma. The
classic appearance of choroidal melanoma is a pigmented dome-shaped tumor with
an exudative retinal detachment. Typically, choroidal melanomas are pigmented
but can also be amelanotic.1 Choroidal melanomas are gray-green, brown, or
yellowish in color and are characterized by subretinal fluid, thickness greater than
or equal to 2 mm, areas of orange pigment (lipofuscin), presence of congested blood
vessels, and growth.2 Absence of drusen and a halo can also be used to differentiate
the lesion. Autofluorescence of the tumor can be used to determine if one of the
hallmark signs is present: hyperautofluorescence in the retinal pigment epithelium
(RPE) that correlates with orange pigment accumulation.3
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OCT has become the gold standard imaging technique for differentiating between
benign and malignant choroidal lesions. OCT instruments have the ability to
measure retinal lesions within 1µm. Small choroidal melanomas are defined as 1.52.4 mm in height and 5-16 mm in diameter, medium melanomas as 2.5-10 mm
height and less than 16 mm diameter, and large melanomas as greater than 10 mm
in height and greater than 16 mm in diameter.4 The challenge to early detection of
choroidal melanoma is its clinical similarities to benign choroidal nevus.
Particularly in the case of small melanomas, the addition of OCT in diagnostic
testing can be very beneficial. In a study comparing small choroidal melanomas
versus similar-sized choroidal nevi, enhanced depth imaging optical coherence
tomography (EDI-OCT) showed abnormalities at all levels of the retina, RPE,
Bruch’s membrane, and choroid. The small choroidal melanomas more often
showed increased tumor thickness, subretinal fluid, lipofuscin deposition, and RPE
atrophy. In addition to the clinical characteristics that were previously established,
EDI-OCT of small choroidal melanomas more often showed the presence of shaggy
photoreceptors, loss of external limiting membrane, loss of inner-outer segment
junction, irregularity of inner plexiform and ganglion cell layers, and intraretinal
edema.3
Although EDI-OCT and autofluorescence are newer ancillary testing modalities
to help diagnose and manage patients with choroidal melanoma, ultrasound is still
quite useful, especially in lesions in the extreme periphery where the OCT laser
cannot reach. Combined A-mode and B-mode ultrasonography are used to image
and measure the size of the tumor. Classic features of choroidal melanoma with Bscan are low-moderate internal reflectivity, choroidal excavation, and shadowing
in the orbit.1 Secondary tumors that metastasize to the eye typically have high
internal reflectivity on B-scan.
Intra-venous fluorescein angiography (IVFA) can also be used in patients where
the OCT laser cannot reach lesions in the extreme periphery. IVFA may detect the
presence of intrinsic tumor circulation present in larger tumors, extensive leakage
with progressive fluorescence, late staining and multiple pinpoint hot spots at the
RPE.1
The choice of treatment for a choroidal melanoma is dependent on several factors
including visual acuity, tumor size, and location, ocular structures involved, and
metastasis. Radioactive plaque brachytherapy and proton beam radiation therapy
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(PBRT) are primarily used in the treatment of small choroidal melanoma. Plaque
radiation, PBRT, and enucleation are used primarily in the treatment of medium
and large melanomas.1 The Collaborative Ocular Melanoma Study (COMS)
compared the effectiveness of brachytherapy to enucleation for treatment of
medium sized choroidal melanomas, and the effectiveness of enucleation with and
without pre-operative external beam radiotherapy for large choroidal melanomas.4
The COMS found there was no difference in five year mortality rate for either
treatment group in both the medium and large melanoma arms of the study. PBRT
has become the “gold standard” treatment for choroidal melanomas due to the high
level of tumor control and higher eye preservation rates without a reduction in
efficacy. However, PBRT is less accessible because there are limited treatment
centers with the required equipment and clinical expertise to administer it.5
Coordination of care with other specialties by the eye care team is crucial after the
diagnosis of a choroidal melanoma. Genetic profiling, imaging for metastasis, and
the determination of the cancer stage are performed. Screening for metastatic
disease may vary but generally includes lung and liver imaging, along with liver
function tests and physical examination. Positron emission tomography/computed
tomography (PET/CT) is often used. Staging of the malignancy is based on the
American Joint Committee on Cancer tumor, node, metastasis (TNM) staging
system.6 Staging and genetic profiling are important because they guide the
treatment plan, determine the patient’s prognosis, and help identify the appropriate
treatment. TNM stages the cancer by tumor size using the thickness and largest
basal diameter. Tumors are assigned to subgroups based on ciliary body
involvement or extraocular extension. Tumors are then divided into groups by the
presence or absence of metastasis and further divided based on the largest diameter
of the largest metastasis. Gene expression profiling (GEP) divides uveal
melanomas into classes 1A, 1B, and 2. Class 1 uveal melanomas are associated
with low risk of metastasis and class 2 has the highest risk of metastasis.7 In general,
choroidal melanomas with a largest basal diameter more than 12 mm and class 2
GEP have the worst prognosis.7 It is hypothesized that larger tumors have been
present longer and, therefore, have had more time to metastasize, and/or larger
tumors are an indicator of increased tumor malignancy and a greater growth rate.8
At the time of diagnosis, about 1.8% of patients are found to have metastasis. 9
After the development of metastatic disease, the median survival is about 13.4
months, with only 8% survival in 2 years.10 The most common site for choroidal

Published by The Athenaeum, 2021

23

Optometric Clinical Practice, Vol. 3 [2021], Iss. 2, Art. 4

melanoma metastasis is the liver (80-90%). Other potential systemic locations
include the lungs, bone, and skin. Rates of metastasis observed in the COMS study
after 5 and 10 years were 25% and 34% respectively.1 Patients with metastasis to
non-liver organ sites were found to have a longer median survival rate than those
with metastasis to the liver. Patients with hepatic metastasis had a median survival
rate of only 6 months.11 Metastasis of choroidal melanoma can occur long after the
primary tumor was definitively treated. Metastasis has been discovered up to 40
years after initial diagnosis, arising from metastatic cells in apparent dormancy.12
Long-term follow-up studies have found up to 49% of choroidal melanoma patients
die from metastatic melanoma.9,10,12
Whole-body screening after the diagnosis of choroidal melanoma can also
discover second primary or synchronous cancers. In a study of 333 patients
diagnosed with choroidal melanoma and subsequently screened with PET/CT, 10%
were diagnosed with a second primary cancer, nearly equal to the percentage found
to have metastasis in that study.6 Multiple primary neoplasms have been reported
to account for 13-16% of all malignancies and are considered to be the sixth most
common presentation of cancer. In a long-term follow-up study, 6% of patients with
uveal melanoma died of a second primary malignancy.12 In another study of
patients with uveal melanoma, PET/CT provided early detection of second primary
cancers in 4.3% of patients. None of these patients reported symptoms that would
have indicated a second primary cancer.13 Radiation from PET/CT screening poses
a second cancer risk. One report indicated the risk to be 0.2%-0.5% per year.14
Therefore, the risk-benefit analysis should be considered when choosing PET/CT
over other imaging techniques. The COMS study concluded there was no
correlation between the treatment of choroidal melanoma and the occurrence of a
second primary tumor.15
In general, second primary cancers are not as uncommon as thought. Cancer
patients have approximately twice the risk of development of a second primary
cancer compared to cancer-free patients of the same sex and age. There has been a
rise in the number of second primary cancers, likely due to improvements in cancer
treatment that allow patients to live longer. There are many potential causes of
second primary malignancies, including environmental risk factors, lifestyle risk
factors, genetic predisposition, polymorphisms for metabolizing enzymes, and
radiation therapy.16
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CONCLUSION
Early diagnosis of choroidal melanoma is important due to the improved survival
rates for patients who are diagnosed when the choroidal melanoma is small. In
addition to the clinical assessment, diagnosis may be aided by ancillary imaging
such as OCT. The prognosis is generally poor due to late diagnosis being common,
and is dependent on choroidal melanoma size, genetic profile, and presence of
metastasis. As demonstrated by this case, whole-body screening for metastasis can
lead to the discovery of second primary tumors. Detection of second primary
tumors occurs at a rate nearly equal to that of metastasis.
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